GlobeNewsWire
12 Nov 2025, 21:30 UTC · 44w ago
Verdict
Headline takes no side. We score ETON +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Eton Pharmaceuticals reported Q2 2026 product sales of $37.6 million, a 99% increase over Q2 2025.
More positive than 99% of claims this week
The company achieved a Q2 2026 non-GAAP fully diluted EPS of $0.43 and EBITDA of $14.1 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
Eton Pharmaceuticals executive leadership will host 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported record revenue with 99% year-over-year growth in product sales and positive EPS/EBITDA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+227.0%
Price agrees with the score
$57.09 vs $17.46 close before publication (Nov 12) · not market-adjusted
ETON chart →